Lung cancer, with the highest incidence in China, is the leading cause of death in cancer patients. Of these, about 85% are patients with non-small cell lung cancer (NSCLC). Therefore, the diagnosis and treatment of patients with lung cancer have always been a top priority nowadays. Fluid biopsy has many advantages, such as safety, convenience, repeatability, low trauma and so on, which are not available in traditional invasive biopsy. In recent years, with the rapid progress of molecular biological detection technology, fluid biopsy, as a new technology, has become the focus of attention. What's more, it contributes to the development of precision treatment and individualized treatment of lung cancer. Liquid biopsy mainly detects circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and exosomes in peripheral blood. We will make an introduce to the detection and clinical applications of ctDNA, CTCs and exocrine in this article, in order that it can provide insights into future clinical treatment for NSCLC. .
【中文题目：液体活检在非小细胞肺癌中的临床应用进展】 【中文摘要：肺癌是我国发病率最高的癌症，也是癌症患者死亡的首要病因。其中，约85%是非小细胞肺癌（non-small cell lung cancer, NSCLC）。肺癌患者的诊断方法和治疗措施一直是重中之重。近年来，随着分子生物学检测技术的快速进步以及精准治疗和个体化治疗的发展，液体活检因其具有传统侵入性活检所不具备的优点而成为关注的焦点，如安全、便捷、重复性、低创伤性等。液体活检作为一种新兴技术，其检测对象主要包括外周血中的循环肿瘤DNA（circulating tumor DNA, ctDNA）、循环肿瘤细胞（circulating tumor cells, CTCs）、外泌体等。本文将对ctDNA、CTCs和外泌体的检测及其在NSCLC患者中的临床应用作一简要综述。 】 【中文关键词：肺肿瘤；液体活检；循环肿瘤DNA；循环肿瘤细胞；外泌体】.
Keywords: Circulating tumor DNA; Circulating tumor cells; Exosomes; Liquid biopsy; Lung neoplasms.